Mall PA
SS-31 NOT FOR HUMANS NOT ON THE LIST
File 11 · synthetic mitochondria-targeted tetrapeptide (cardiolipin-binding)

SS-31

Also called: elamipretide, Forzinity, Bendavia, MTP-131, D-Arg-Dmt-Lys-Phe-NH2

Not namedApproved drug (for a different use)

SS-31 is a four-amino-acid peptide that concentrates in the inner membrane of mitochondria, where it binds cardiolipin, a lipid needed for efficient energy production. Under the name elamipretide (Forzinity), it became the first FDA-approved mitochondria-targeted drug in September 2025, for the rare genetic disease Barth syndrome.

Why the gym talks about it

It is discussed in longevity and endurance circles as a 'mitochondria repair' peptide, largely because of striking results in aged mice.

What the research actually found

  • animal (mouse)A single treatment restored skeletal-muscle mitochondrial energy production in aged mice toward young levels within an hour, and 8 days of treatment increased whole-animal endurance. Source
  • animal (mouse)In aged mice, SS-31 reversed age-related redox stress and improved exercise tolerance. Source
  • human randomized trial (phase 3, negative)In the phase 3 MMPOWER-3 trial (218 adults with primary mitochondrial myopathy), elamipretide did not beat placebo on its primary endpoints of 6-minute walk distance and fatigue. Source
  • approved drug data (rare disease)FDA granted accelerated approval on Sept 19, 2025 for improving muscle strength in Barth syndrome patients weighing at least 30 kg, based on knee-extensor strength; continued approval depends on confirmatory trials. Source

Human evidence: approved drug (for a different use). Approved (accelerated) only for Barth syndrome; a large trial in primary mitochondrial myopathy was negative; there are no trials in healthy or athletic people.

Tested lifters

Not named on the 2026 list. Since its 2025 FDA approval it is no longer covered by the S0 non-approved catch-all, and its mechanism does not fit an S2 or S4 subsection.

Probably low, but unconfirmed; it is not explicitly cleared either. Check Global DRO or USADA. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.

FDA status

FDA-approved as Forzinity (elamipretide HCl) on Sept 19, 2025 under accelerated approval for Barth syndrome (patients at least 30 kg). Any other use is off-label, and 'research' SS-31 is not the approved product. It is not on the interim 503A categories list.

As of 2026-10-01.

Known and theoretical risks

  • Injection-site reactions are the most common adverse reaction with the approved drug. Source
  • The approved formulation contains benzyl alcohol and is not for use in newborns. Source
  • No safety data exist for use in healthy people, and gray-market 'research' material is not the approved, quality-controlled drug. Source

Quick answers

Is SS-31 banned for drug-tested lifters?

Not named on the 2026 list. Since its 2025 FDA approval it is no longer covered by the S0 non-approved catch-all, and its mechanism does not fit an S2 or S4 subsection. Probably low, but unconfirmed; it is not explicitly cleared either. Check Global DRO or USADA. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.

Is SS-31 FDA approved?

FDA-approved as Forzinity (elamipretide HCl) on Sept 19, 2025 under accelerated approval for Barth syndrome (patients at least 30 kg). Any other use is off-label, and 'research' SS-31 is not the approved product. It is not on the interim 503A categories list.

How strong is the human evidence for SS-31?

Approved drug (for a different use). Approved (accelerated) only for Barth syndrome; a large trial in primary mitochondrial myopathy was negative; there are no trials in healthy or athletic people.

Sources

Research-use-only information file. Nothing here is medical advice or instructions for use. Not evaluated by the FDA. Talk to your doctor.

More files

Back to the basement